Evaluation of subclinical atherosclerosis in Egyptian psoriatic patients

Griffiths, 2007, Pathogenesis and clinical features of psoriasis, Lancet, 370, 263, 10.1016/S0140-6736(07)61128-3 Kremers, 2007, Heart disease in psoriasis, J Am Acad Dermatol, 57, 347, 10.1016/j.jaad.2007.02.007 Robinson, 2006, IMID Study Group. Co-occurrence and comorbidities in patient with immune-mediated inflammatory disorders: an exploration using US health care claims data, 2001–2002, Curr Med Res Opin, 22, 989, 10.1185/030079906X104641 Hansson, 2006, The immune response in atherosclerosis: a double-edged sword, Nat Rev Immunol, 6, 508, 10.1038/nri1882 Naghavi, 2006, From vulnerable plaque to vulnerable patient–Part III: executive summary of the screening for heart attack prevention and education (SHAPE) task force report, Am J Cardiol, 98, 2H, 10.1016/j.amjcard.2006.03.002 Kimball, 2008, National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening, J Am Acad Dermatol, 58, 1031, 10.1016/j.jaad.2008.01.006 Gottlieb, 2008, Psoriasis comorbidities, J Dermatol Treat, 19, 5, 10.1080/09546630701364768 Celermajer, 1992, Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis, Lancet, 340, 1111, 10.1016/0140-6736(92)93147-F van de Kerkhof, 1997, The Psoriasis Area and Severity Index and alternative approaches for the assessment of severity: persisting areas of confusion, Br J Dermatol, 137, 661, 10.1111/j.1365-2133.1997.tb03819.x Fathi, 2001, Noninvasive tests of vascular function and structure: why and how to perform them, Am Heart J, 141, 694, 10.1067/mhj.2001.114972 Kassem, 2011, Non traditional risk factors of carotid atherosclerosis in rheumatoid arthritis, Egypt Rheumatol, 33, 113, 10.1016/j.ejr.2011.03.005 Roman, 2003, Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematous, N Engl J Med, 349, 2399, 10.1056/NEJMoa035471 Simons, 1999, Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestation of ARTerial Disease), Circulation, 100, 951, 10.1161/01.CIR.100.9.951 Copeland, 2008, Psoriatic arthritis treatment approach, Hosp Pharm, 15, 207 Gerwal, 2008, SHARE and SHARE-AP Investigators. Prevalence and predictors of subclinical atherosclerosis among asymptomatic “low risk” individuals in a multiethnic population, Atherosclerosis, 197, 435, 10.1016/j.atherosclerosis.2007.06.020 El-Mongy, 2010, Subclinical atherosclerosis in patients with chronic psoriasis: a potential association, J Eur Acad Dermatol Venereol, 24, 661, 10.1111/j.1468-3083.2009.03481.x Kimhi, 2007, Prevalance and risk factors of atherosclerosis in patients with psoriatic arthritis, Semin Arthritis Rheum, 36, 203, 10.1016/j.semarthrit.2006.09.001 Tam, 2008, Subclinical carotid atherosclerosis in patients with psoriatic arthritis, Arthritis Rheum, 59, 1322, 10.1002/art.24014 Balci, 2009, Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis, J Eurn Acad Dermatol Venereol, 23, 1, 10.1111/j.1468-3083.2008.02936.x Enany, 2012, Carotid intima-media thickness and serum leptin in psoriasis, Herz, 37, 527, 10.1007/s00059-011-3547-z Gonzalez-Juanatey, 2007, Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors, Arthritis Rheum, 57, 287, 10.1002/art.22530 Sahar, 2009, Susceptibility to atherosclerosis in patients with psoriasis and psoriatic arthritis as determined by increased carotid artery intima-media thickness, Egypt J Dermatol Androl, 20, 159 Sommer, 2006, Increased prevalence of metabolic syndrome in patients with moderate to severe psoriasis, Arch Dermatol Res, 298, 321, 10.1007/s00403-006-0703-z Hahn, 2007, The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia, J Autoimmun, 28, 69, 10.1016/j.jaut.2007.02.004 O’Leary, 1999, Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group, N Engl J Med, 340, 14, 10.1056/NEJM199901073400103 Gelfand, 2006, Risk of myocardial infarction in patients with psoriasis, JAMA, 296, 1735, 10.1001/jama.296.14.1735 Wakkee, 2007, Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients, Atherosclerosis, 190, 1, 10.1016/j.atherosclerosis.2006.07.011 Soy, 2009, Susceptibility to atherosclerosis in patients with psoriasis and psoriatic arthritis as determined by carotid-femoral (aortic) pulse-wave velocity measurement. Article in Spanish, Rev Esp Cardiol, 62, 96, 10.1016/S0300-8932(09)70027-2 Eder, 2008, Subclinical atherosclerosis in psoriatic arthritis: a case-control study, J Rheumatol, 35, 877 Christophers, 2007, Comorbidities in psoriasis, Clin Dermatol, 25, 529, 10.1016/j.clindermatol.2007.08.006 Saleh, 2013, Platelet activation: a link between psoriasis per se and subclinical atherosclerosis–a case-control study, Br J Dermatol, 169, 68, 10.1111/bjd.12285 Dowlatshahi, 2013, Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam study, J Invest Dermatol, 133, 2347, 10.1038/jid.2013.131